The pharmacological management of erectile dysfunction – Update 2016
Erectile dysfunction (ED) is a trivial condition with a prevailing incidence worldwide. Phosphodiesterase-5 inhibitors (PDE-5) have revolutionised the treatment of ED and are regarded as one of the most successful drug groups in modern medicine. Generally PDE-5 inhibitors are well tolerated and the...
Enregistré dans:
Auteur principal: | André Marais |
---|---|
Format: | article |
Langue: | EN |
Publié: |
AOSIS
2016
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/ac2c0879c48f4050a954caea45b7c80c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Erectile dysfunction in men with diabetes (literature review). Part 2
par: Е.V. Luchytskiy, et autres
Publié: (2021) -
Pathological Significance of Macrophages in Erectile Dysfunction Including Peyronie’s Disease
par: Yasuyoshi Miyata, et autres
Publié: (2021) -
Erectile dysfunction as a manifestation of urogenital autonomic neuropathy in patients with type 1 diabetes: epidemiology, classification, pathophysiology, diagnosis and treatment options
par: Gagik Radikovich Galstyan, et autres
Publié: (2014) -
Efficacy and safety of short- and long-term, regular and on-demand regimens of phosphodiesterase type 5 inhibitors in treating erectile dysfunction after nerve-sparing radical prostatectomy: a systematic review and meta-analysis
par: Tian D, et autres
Publié: (2017) -
Consensus of experts from the Russian Medical Society of Arterial Hypertension. Arterial hypertension and erectile dysfunction
par: Tatiana A. Alekseeva, et autres
Publié: (2021)